Spero Therapeutics (SPRO) Other Operating Expenses (2022 - 2025)
Spero Therapeutics' (SPRO) quarterly Other Operating Expenses came in at $587000.0 in Q3 2025, down 88.94% on a QoQ basis from $5.3 million in Q3 2023.
Spero Therapeutics (SPRO) Other Operating Expenses (2022 - 2025) Analysis & Trends
Spero Therapeutics (SPRO) has 3 years of Other Operating Expenses data on file, last reported at $587000.0 in Q3 2025.
- Quarterly Other Operating Expenses changed N/A year-over-year to $587000.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $587000.0 (changed N/A YoY) and the FY2025 annual result came in at $587000.0, changed N/A from the prior year.
- Other Operating Expenses retreated to $587000.0 in Q3 2025, from $5.3 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $11.8 million in Q2 2022 to a low of $587000.0 in Q3 2025.
- A 3-year average of $5.9 million and a median of $5.3 million in 2023 frame the typical range for Other Operating Expenses.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 587,000.00 |
| Sep 30, 2023 | 5.31 Mn |
| Jun 30, 2022 | 11.85 Mn |